Your session is about to expire
← Back to Search
Defibrotide for COVID-19
Study Summary
This trial will test if the drug defibrotide is safe and effective in treating COVID-19 pneumonia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 20 Patients • NCT02876601Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a known allergy or hypersensitivity to DF (the specific substance or medication).I am 18 years old or older.You currently have a confirmed case of COVID-19.I am currently using medication to dissolve blood clots.I need more than one medication to maintain my blood pressure for cohort 1, and more than two for cohort 2.I am currently experiencing significant bleeding.I am on a blood thinner for a clot and have had no bleeding after 24 hours.You are expected to live for at least 24 hours.My lung scans show signs of infection in both lungs.You have a moderate to severe illness according to the WHO scale.I am taking a preventive blood thinner for cohort 1.
- Group 1: Defibrotide
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
May I partake in this research endeavor?
"This research seeks 42 individuals with COVID-19 between 18 and 100 years old. To qualify, applicants must have a WHO ordinal score of 4 to 7; an allowance for prophylactic anticoagulation in cohort 1; therapeutic dose anticoagulation without evidence of bleeding after 24 hours' time in cohort 2; age over the legal limit of consent; and a life expectancy that exceeds one day."
Does the protocol for this clinical trial encompass individuals aged 75 and above?
"The parameters for admission to this trial require applicants aged between 18 and 100. There are 141 trials accessible to those under the age of majority, while 906 studies cater towards individuals over 65 years old."
What prior research has been performed on Defibrotide?
"Currently, there are 4 clinical trials exploring Defibrotide with 0 of them in Phase 3. Of the 9 total sites that host these studies, the majority are located in Boston, Massachusetts."
Are there any vacancies left for participants in this examination?
"Affirmative. Clinicaltrials.gov data reveals that this research protocol is actively enrolling participants since its initial posting on January 1st 2021, with the most recent edit happening on July 23rd 2021; 42 people are needed across one medical facility."
How many individuals are currently taking part in this examination?
"Affirmative, clinicaltrials.gov data suggests that this trial is now open to applicants. The protocol was initially publicized on January first 2021 and has been recently revised on July twenty-third 2021. There are 42 openings at a single location."
What potential risks does Defibrotide pose to individuals?
"There is limited evidence to suggest defibrotide's safety, so it was awarded a score of 2."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger